Canagliflozin

Generic name: Pronounced as (kan'' a gli floe' zin)
Brand names
  • Invokana®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 11/15/2020

Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Canagliflozin is also used to reduce the risk of stroke, heart attack, or death in people who have type 2 diabetes along with heart and blood vessel disease. Canagliflozin is also used to reduce the risk of end-stage kidney disease, worsening of kidney function, needing to be hospitalized for heart failure, and cardiovascular death in people who have type 2 diabetes along with severe kidney disease. Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Canagliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood).

Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.

Canagliflozin comes as a tablet to take by mouth. It is usually taken once a day before breakfast or the first main meal of the day. Take canagliflozin at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take canagliflozin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may start you on a low dose of canagliflozin and gradually increase your dose.

Canagliflozin controls type 2 diabetes but does not cure it. Continue to take canagliflozin even if you feel well. Do not stop taking canagliflozin without talking to your doctor.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking canagliflozin,

  • tell your doctor and pharmacist if you are allergic (rash, hives, swelling of your face, lips, tongue, or throat, or difficulty breathing) to canagliflozin, any other medications, or any of the ingredients in canagliflozin tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: angiotensin-converting enzyme (ACE) inhibitors such as benazepril (Lotensin, in Lotrel), captopril, enalapril (Vasotec, in Vaseretic), fosinopril, lisinopril (in Zestoretic), moexipril (Univasc, in Uniretic), perindopril (Aceon, in Prestalia), quinapril (Accupril, in Accuretic, in Quinaretic), ramipril (Altace), and trandolapril (Mavik, in Tarka); angiotensin receptor blockers such as azilsartan (Edarbi, in Edarbyclor), candesartan (Atacand, in Atacand HCT), eprosartan (Teveten), irbesartan (Avapro, in Avalide), losartan (Cozaar, in Hyzaar), olmesartan (Benicar, in Azor, in Benicar HCT, in Tribenzor), telmisartan (Micardis, in Micardis HCT, in Twynsta), and valsartan (Diovan, in Diovan HCT, in Exforge); digoxin (Lanoxin); diuretics ('water pills'); insulin; other medications for diabetes; phenobarbital; phenytoin (Dilantin, Phenytek); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); and ritonavir (Norvir, in Kaletra). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you are on dialysis. Your doctor may tell you not to take canagliflozin.

  • tell your doctor if you regularly drink alcohol or sometimes drink large amounts of alcohol in a short time (binge drinking), or are on a low sodium diet. Also, tell your doctor if you have ever had an amputation, or have ever had heart disease, peripheral vascular disease (narrowing of blood vessels in feet, legs, or arms causing numbness, pain, or coldness in that part of the body), neuropathy (nerve damage that causes tingling, numbness, and pain, usually in your hands and feet), foot ulcers or sores, low blood pressure, urinary tract infections, or urinary problems, pancreatic disease including pancreatitis (swelling of the pancreas) or have had surgery on your pancreas, yeast infections in the genital area, osteoporosis (a condition in which the bones become thin and weak and break easily), kidney or liver disease. If you are male, tell your doctor if you have never been circumcised. Tell your doctor if you are eating less due to illness, surgery, or a change in your diet or if you are unable to eat or drink normally due to nausea, vomiting, diarrhea, or if you become dehydrated from being in the sun too long.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. Do not breastfeed while you are taking canagliflozin. If you become pregnant while taking canagliflozin, call your doctor.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking canagliflozin.

  • alcohol may cause a change in blood sugar. Ask your doctor about the safe use of alcoholic beverages while you are taking canagliflozin.

  • you should know that canagliflozin may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. If you have this problem, call your doctor. This problem is more common when you first start taking canagliflozin. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

  • ask your doctor what to do if you get sick, develop an infection or fever, experience unusual stress, or are injured. These conditions can affect your blood sugar and the amount of canagliflozin you may need.

Be sure to follow all exercise and dietary recommendations made by your doctor or dietitian. It is important to eat a healthful diet and exercise regularly.

Follow your doctor's instructions about drinking enough fluids throughout the day while you are on this medication.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

This medication may cause changes in your blood sugar. You should know the symptoms of low and high blood sugar and what to do if you have these symptoms.

  • Canagliflozin may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • urinating a lot, including at night

    • increased thirst

    • constipation

    • dry mouth

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:

    • frequent, urgent, burning, or painful urination

    • decrease in amount of urine

    • urine that is cloudy, red, pink, or brown

    • strong smelling urine

    • pelvic or rectal pain

    • (in women) vaginal odor, white or yellowish vaginal discharge (may be lumpy or look like cottage cheese), or vaginal itching

    • (in men) redness, itching, or swelling of the penis; rash on the penis; foul smelling discharge from the penis; or pain in the skin around the penis

    • feeling tired, weak, or uncomfortable; along with a fever and pain, tenderness, redness, and swelling of the genitals or the area between the genitals and the rectum

  • If you experience any of the following symptoms, stop taking canagliflozin and call your doctor immediately or get emergency medical treatment:

    • rash

    • hives

    • itching

    • difficulty swallowing

    • swelling of the face, throat, tongue, lips, mouth, or eyes

    • hoarseness

  • If you experience any of the following symptoms of ketoacidosis (a serious condition that may develop if high blood sugar is not treated), stop taking canagliflozin and call your doctor immediately or get emergency medical treatment. If possible, check for ketones in your urine if you have these symptoms, even if your blood sugar is less than 250 mg/dL:

    • nausea

    • vomiting

    • stomach-area pain

    • tiredness

    • difficulty breathing

  • You should know that canagliflozin can increase the risk of having a lower limb (toe, foot, or leg) amputation. Your doctor will tell you how to take care of your legs and feet properly to help avoid infections and complications that could lead to an amputation. Follow the doctor's instructions carefully and call your doctor right away if you have any pain, tenderness, sores, ulcers, or swollen, warm, reddened area in your leg or foot, fever or chills, or other signs and symptoms of infection.

  • Canagliflozin may increase the chance of having a fracture (broken bone), particularly in the upper arms, wrists, or hands. Talk to your doctor about the risks of taking this medication.

  • Canagliflozin may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor and the laboratory. Your doctor will order a lab test before and during your treatment with canagliflozin to check how well your kidneys are working. Your blood sugar levels should be checked regularly to determine your response to canagliflozin. Your doctor will order other lab tests, including glycosylated hemoglobin (HbA1c), to check your response to canagliflozin. Your doctor will also tell you how to check your response to this medication by measuring your blood sugar levels at home. Follow these instructions carefully.

Before having any laboratory test, tell your doctor and the laboratory personnel that you are taking canagliflozin. Because of the way this medication works, your urine may test positive for glucose.

You should always wear a diabetic identification bracelet to be sure you get proper treatment in an emergency.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

  • Invokamet® (containing Canagliflozin and Metformin)

Drug Interaction
Moxifloxacin Moxifloxacin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.
Repaglinide Repaglinide Canagliflozin may increase the hypoglycemic activities of Repaglinide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection Canagliflozin may increase the hypoglycemic activities of Insulin glargine.
Bisacodyl Bisacodyl The risk or severity of adverse effects can be increased when Canagliflozin is combined with Bisacodyl.
Candesartan Candesartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Candesartan.
Cilostazol Cilostazol Cilostazol may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Diphenoxylate Diphenoxylate The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The serum concentration of Canagliflozin can be increased when it is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Fenofibrate Fenofibrate Fenofibrate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Guanfacine Guanfacine Guanfacine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium Hydroxide Magnesium Hydroxide Canagliflozin may increase the excretion rate of Magnesium hydroxide which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium Oxide Magnesium Oxide The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium oxide.
Miglitol Miglitol Canagliflozin may increase the hypoglycemic activities of Miglitol.
Mycophenolate Mycophenolate Mycophenolic acid may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Olsalazine Olsalazine Olsalazine may increase the hypoglycemic activities of Canagliflozin.
Paregoric Paregoric The serum concentration of Morphine can be increased when it is combined with Canagliflozin.
Penbutolol Penbutolol The therapeutic efficacy of Acebutolol can be increased when used in combination with Canagliflozin.
Pentazocine Pentazocine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentazocine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The risk or severity of adverse effects can be increased when Canagliflozin is combined with Polyethylene glycol.
Potassium Potassium Potassium cation may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Canagliflozin.
Psyllium Psyllium The risk or severity of adverse effects can be increased when Canagliflozin is combined with Plantago seed.
Ranitidine Ranitidine Ranitidine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Reserpine Reserpine The serum concentration of Canagliflozin can be increased when it is combined with Reserpine.
Rizatriptan Rizatriptan Rizatriptan may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Sumatriptan Sumatriptan The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sumatriptan.
Tacrolimus Tacrolimus The serum concentration of Canagliflozin can be increased when it is combined with Tacrolimus.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.
Triamcinolone Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Canagliflozin.
Ampicillin Injection Ampicillin Injection Ampicillin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Doxycycline Injection Doxycycline Injection Doxycycline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Fluconazole Injection Fluconazole Injection The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Fluconazole.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection Hydromorphone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Levofloxacin Injection Levofloxacin Injection The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.
Meperidine Injection Meperidine Injection Meperidine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methylprednisolone Injection Methylprednisolone Injection The risk or severity of hyperglycemia can be increased when Canagliflozin is combined with Methylprednisolone.
Metoclopramide Injection Metoclopramide Injection Metoclopramide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Morphine Injection Morphine Injection The serum concentration of Morphine can be increased when it is combined with Canagliflozin.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Canagliflozin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine Amphetamine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cyclosporine Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.
Enoxaparin Injection Enoxaparin Injection The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Canagliflozin.
Torsemide Torsemide The risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.
Olanzapine Olanzapine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.
Eprosartan Eprosartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Eprosartan.
Hydroxychloroquine Hydroxychloroquine The therapeutic efficacy of Canagliflozin can be increased when used in combination with Hydroxychloroquine.
Meloxicam Meloxicam The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Meloxicam.
Pantoprazole Pantoprazole Pantoprazole may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Telmisartan Telmisartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Telmisartan.
Temozolomide Temozolomide Temozolomide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Zaleplon Zaleplon Zaleplon may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Linezolid Linezolid Linezolid may increase the orthostatic hypotensive activities of Canagliflozin.
Trimipramine Trimipramine The serum concentration of Canagliflozin can be increased when it is combined with Trimipramine.
Perindopril Perindopril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Canagliflozin.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Sirolimus Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Canagliflozin.
Epinephrine Injection Epinephrine Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.
Eplerenone Eplerenone Canagliflozin may increase the excretion rate of Eplerenone which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Canagliflozin.
Olmesartan Olmesartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Olmesartan.
Zonisamide Zonisamide The therapeutic efficacy of Canagliflozin can be increased when used in combination with Zonisamide.
Aripiprazole Aripiprazole The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.
Atomoxetine Atomoxetine Atomoxetine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Atazanavir Atazanavir The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Atazanavir.
Almotriptan Almotriptan Almotriptan may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The risk or severity of adverse effects can be increased when Canagliflozin is combined with Polyethylene glycol.
Rosuvastatin Rosuvastatin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosuvastatin.
Vardenafil Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Canagliflozin.
Emtricitabine Emtricitabine Emtricitabine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Memantine Memantine Memantine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Tegaserod Tegaserod The serum concentration of Tegaserod can be increased when it is combined with Canagliflozin.
Tadalafil Tadalafil Canagliflozin may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.
Fosamprenavir Fosamprenavir The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.
Gemifloxacin Gemifloxacin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gemifloxacin.
Progesterone Progesterone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.
Oxandrolone Oxandrolone Oxandrolone may increase the hypoglycemic activities of Canagliflozin.
Protriptyline Protriptyline Protriptyline may decrease the hypoglycemic activities of Canagliflozin.
Rifaximin Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.
Duloxetine Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Canagliflozin is combined with Duloxetine.
Norethindrone Norethindrone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.
Tinidazole Tinidazole Tinidazole may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Bosentan Bosentan The therapeutic efficacy of Bosentan can be increased when used in combination with Canagliflozin.
Cefditoren Cefditoren Cefdinir may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Eszopiclone Eszopiclone Eszopiclone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ganciclovir Ganciclovir Ganciclovir may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection Canagliflozin may increase the hypoglycemic activities of Insulin aspart.
Ribavirin Ribavirin Ribavirin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Valganciclovir Valganciclovir Valganciclovir may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Adefovir Adefovir Adefovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine Amphetamine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pramlintide Injection Pramlintide Injection Canagliflozin may increase the hypoglycemic activities of Pramlintide.
Exenatide Injection Exenatide Injection Canagliflozin may increase the hypoglycemic activities of Exenatide.
Isocarboxazid Isocarboxazid Isocarboxazid may increase the orthostatic hypotensive activities of Canagliflozin.
Ramelteon Ramelteon Ramelteon may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Fentanyl Fentanyl Fentanyl may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pregabalin Pregabalin The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Canagliflozin.
Deferasirox Deferasirox The metabolism of Canagliflozin can be decreased when combined with Deferasirox.
Tipranavir Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Canagliflozin.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection Canagliflozin may increase the hypoglycemic activities of Insulin detemir.
Ranolazine Ranolazine The serum concentration of Canagliflozin can be increased when it is combined with Ranolazine.
Rasagiline Rasagiline Rasagiline may increase the orthostatic hypotensive activities of Canagliflozin.
Sitagliptin Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Canagliflozin.
Varenicline Varenicline Varenicline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Albuterol Albuterol Salbutamol may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Paliperidone Paliperidone The serum concentration of Canagliflozin can be increased when it is combined with Paliperidone.
Bortezomib Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin.
Clofarabine Injection Clofarabine Injection Clofarabine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection Canagliflozin may increase the hypoglycemic activities of Insulin glulisine.
Lubiprostone Lubiprostone Lubiprostone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Posaconazole Posaconazole The serum concentration of Canagliflozin can be increased when it is combined with Posaconazole.
Aliskiren Aliskiren The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Aliskiren.
Bismuth Subsalicylate Bismuth Subsalicylate Bismuth subsalicylate may increase the hypoglycemic activities of Canagliflozin.
Darunavir Darunavir The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Darunavir.
Pemetrexed Injection Pemetrexed Injection Canagliflozin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Nabilone Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.
Vorinostat Vorinostat The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.
Sorafenib Sorafenib The metabolism of Canagliflozin can be decreased when combined with Sorafenib.
Sunitinib Sunitinib Canagliflozin may increase the hypoglycemic activities of Sunitinib.
Lapatinib Lapatinib The serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.
Levocetirizine Levocetirizine Levocetirizine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pegaptanib Injection Pegaptanib Injection Pegaptanib may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Dasatinib Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.
Azacitidine Injection Azacitidine Injection Azacitidine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The risk or severity of adverse effects can be increased when Canagliflozin is combined with Castor oil.
Temsirolimus Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.
Lenalidomide Lenalidomide Lenalidomide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Nilotinib Nilotinib The serum concentration of Canagliflozin can be increased when it is combined with Nilotinib.
Toremifene Toremifene The serum concentration of Canagliflozin can be increased when it is combined with Toremifene.
Budesonide Budesonide The risk or severity of hyperglycemia can be increased when Canagliflozin is combined with Budesonide.
Desmopressin Desmopressin Desmopressin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Doripenem Injection Doripenem Injection Doripenem may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Arsenic Trioxide Injection Arsenic Trioxide Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine Desvenlafaxine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Cevimeline Cevimeline Cevimeline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Nebivolol Nebivolol The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nebivolol.
Tretinoin Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Canagliflozin.
Bendamustine Injection Bendamustine Injection The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin.
Certolizumab Injection Certolizumab Injection Canagliflozin may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.
Daptomycin Injection Daptomycin Injection Daptomycin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methylnaltrexone Injection Methylnaltrexone Injection Methylnaltrexone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Silodosin Silodosin The serum concentration of Silodosin can be increased when it is combined with Canagliflozin.
Midazolam Midazolam Canagliflozin may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.
Naltrexone Injection Naltrexone Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Naltrexone.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Eltrombopag Eltrombopag The metabolism of Canagliflozin can be decreased when combined with Eltrombopag.
Milnacipran Milnacipran Milnacipran may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Plerixafor Injection Plerixafor Injection Plerixafor may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Sodium Phosphate Sodium Phosphate Canagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.
Fesoterodine Fesoterodine Fesoterodine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Betaxolol Betaxolol The therapeutic efficacy of Canagliflozin can be increased when used in combination with Betaxolol.
Iloperidone Iloperidone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.
Prasugrel Prasugrel Prasugrel may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Everolimus Everolimus The serum concentration of Everolimus can be increased when it is combined with Canagliflozin.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Canagliflozin.
Dronedarone Dronedarone The serum concentration of Dronedarone can be increased when it is combined with Canagliflozin.
Pralatrexate Injection Pralatrexate Injection Pralatrexate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Palonosetron Injection Palonosetron Injection Palonosetron may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Saxagliptin Saxagliptin Canagliflozin may increase the hypoglycemic activities of Saxagliptin.
Telavancin Injection Telavancin Injection Telavancin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Romidepsin Injection Romidepsin Injection The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.
Tapentadol Tapentadol The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tapentadol.
Topotecan Topotecan The serum concentration of Topotecan can be increased when it is combined with Canagliflozin.
Pazopanib Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.
Asenapine Asenapine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.
Levonorgestrel Levonorgestrel The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.
Oxymorphone Oxymorphone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxymorphone.
Liraglutide Injection Liraglutide Injection Canagliflozin may increase the hypoglycemic activities of Liraglutide.
Dalfampridine Dalfampridine Dalfampridine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Cabazitaxel Injection Cabazitaxel Injection The serum concentration of Canagliflozin can be increased when it is combined with Cabazitaxel.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Lurasidone Lurasidone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.
Acetaminophen Injection Acetaminophen Injection Acetaminophen may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ipilimumab Injection Ipilimumab Injection Ipilimumab may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Terbutaline Injection Terbutaline Injection Terbutaline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Azilsartan Azilsartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Azilsartan medoxomil.
Roflumilast Roflumilast Roflumilast may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Linagliptin Linagliptin The serum concentration of Canagliflozin can be increased when it is combined with Linagliptin.
Telaprevir Telaprevir The serum concentration of Glecaprevir can be increased when it is combined with Canagliflozin.
Potassium Iodide Potassium Iodide Potassium Iodide may increase the hyperkalemic activities of Canagliflozin.
Triptorelin Injection Triptorelin Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.
Rivaroxaban Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.
Ticagrelor Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Canagliflozin.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.
Ruxolitinib Ruxolitinib Ruxolitinib may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Vandetanib Vandetanib The serum concentration of Canagliflozin can be increased when it is combined with Vandetanib.
Clobazam Clobazam The serum concentration of Clobazam can be increased when it is combined with Canagliflozin.
Vemurafenib Vemurafenib The serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.
Ivacaftor Ivacaftor The serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.
Deferiprone Deferiprone Deferiprone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Axitinib Axitinib The serum concentration of Axitinib can be increased when it is combined with Canagliflozin.
Crizotinib Crizotinib The serum concentration of Canagliflozin can be increased when it is combined with Crizotinib.
Cabergoline Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Canagliflozin.
Naloxone Injection Naloxone Injection Naloxone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ambrisentan Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.
Fondaparinux Injection Fondaparinux Injection Fondaparinux may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Carfilzomib Injection Carfilzomib Injection The serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.
Iloprost Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Canagliflozin.
Enzalutamide Enzalutamide The serum concentration of Canagliflozin can be increased when it is combined with Enzalutamide.
Mirabegron Mirabegron The serum concentration of Canagliflozin can be increased when it is combined with Mirabegron.
Regorafenib Regorafenib The serum concentration of Canagliflozin can be increased when it is combined with Regorafenib.
Bosutinib Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.
Corticotropin, Repository Injection Corticotropin, Repository Injection The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Canagliflozin.
Linaclotide Linaclotide The risk or severity of adverse effects can be increased when Canagliflozin is combined with Linaclotide.
Lorcaserin Lorcaserin Canagliflozin may increase the hypoglycemic activities of Mecasermin.
Teduglutide Injection Teduglutide Injection Teduglutide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Alogliptin Alogliptin Canagliflozin may increase the hypoglycemic activities of Alogliptin.
Ponatinib Ponatinib The serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.
Pomalidomide Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.
Apixaban Apixaban The serum concentration of Apixaban can be increased when it is combined with Canagliflozin.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The serum concentration of Dabrafenib can be increased when it is combined with Canagliflozin.
Trametinib Trametinib Canagliflozin may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.
Dolutegravir Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Canagliflozin.
Afatinib Afatinib The serum concentration of Afatinib can be increased when it is combined with Canagliflozin.
Levomilnacipran Levomilnacipran The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.
Ertapenem Injection Ertapenem Injection Ertapenem may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Vortioxetine Vortioxetine Canagliflozin may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.
Lomitapide Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Canagliflozin.
Avanafil Avanafil The risk or severity of hypotension can be increased when Avanafil is combined with Canagliflozin.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.
Simeprevir Simeprevir The serum concentration of Canagliflozin can be increased when it is combined with Simeprevir.
Sofosbuvir Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.
Dapagliflozin Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.
Apremilast Apremilast Canagliflozin may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa Droxidopa The risk or severity of Cardiac Arrhythmia can be increased when Droxidopa is combined with Canagliflozin.
Ceritinib Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin.
Albiglutide Injection Albiglutide Injection Canagliflozin may increase the hypoglycemic activities of Albiglutide.
Belinostat Injection Belinostat Injection The serum concentration of Belinostat can be increased when it is combined with Canagliflozin.
Idelalisib Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin.
Testosterone Injection Testosterone Injection Testosterone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Empagliflozin Empagliflozin Canagliflozin may increase the diuretic activities of Empagliflozin.
Vorapaxar Vorapaxar The serum concentration of Canagliflozin can be increased when it is combined with Vorapaxar.
Hydrocodone Hydrocodone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocodone.
Suvorexant Suvorexant The serum concentration of Canagliflozin can be increased when it is combined with Suvorexant.
Dulaglutide Injection Dulaglutide Injection Canagliflozin may increase the hypoglycemic activities of Dulaglutide.
Edoxaban Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.
Methamphetamine Methamphetamine Metamfetamine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Tasimelteon Tasimelteon Canagliflozin may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.
Riociguat Riociguat The risk or severity of adverse effects can be increased when Canagliflozin is combined with Riociguat.
Lanreotide Injection Lanreotide Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.
Nintedanib Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.
Risperidone Injection Risperidone Injection Canagliflozin may increase the hypotensive activities of Risperidone.
Palbociclib Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Canagliflozin.
Insulin Human Inhalation Insulin Human Inhalation Canagliflozin may increase the hypoglycemic activities of Insulin human.
Lenvatinib Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.
Naloxegol Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.
Panobinostat Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.
Haloperidol Injection Haloperidol Injection The serum concentration of Canagliflozin can be increased when it is combined with Haloperidol.
Amiloride Amiloride Amiloride may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection Isavuconazonium Injection The serum concentration of Canagliflozin can be increased when it is combined with Isavuconazonium.
Macitentan Macitentan Canagliflozin may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.
Flibanserin Flibanserin The serum concentration of Canagliflozin can be increased when it is combined with Flibanserin.
Rolapitant Rolapitant The serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.
Prednisolone Prednisolone The risk or severity of hyperglycemia can be increased when Canagliflozin is combined with Prednisolone.
Daclatasvir Daclatasvir The serum concentration of Canagliflozin can be increased when it is combined with Daclatasvir.
Brexpiprazole Brexpiprazole The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.
Penicillin G Procaine Injection Penicillin G Procaine Injection Canagliflozin may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.
Eluxadoline Eluxadoline The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection Canagliflozin may increase the hypoglycemic activities of Insulin degludec.
Cobimetinib Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.
Osimertinib Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Canagliflozin.
Ixazomib Ixazomib Canagliflozin may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.
Lesinurad Lesinurad Canagliflozin may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dexamethasone Injection Dexamethasone Injection The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Canagliflozin.
Brivaracetam Injection Brivaracetam Injection Brivaracetam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Venetoclax Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Canagliflozin.
Cobicistat Cobicistat The serum concentration of Canagliflozin can be increased when it is combined with Cobicistat.
Selexipag Selexipag The serum concentration of Selexipag can be increased when it is combined with Canagliflozin.
Furosemide Injection Furosemide Injection The risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.
Rucaparib Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Canagliflozin.
Lixisenatide Injection Lixisenatide Injection Canagliflozin may increase the hypoglycemic activities of Lixisenatide.
Doxepin (Insomnia) Doxepin (Insomnia) Doxepin may decrease the hypoglycemic activities of Canagliflozin.
Plecanatide Plecanatide The risk or severity of adverse effects can be increased when Canagliflozin is combined with Plecanatide.
Deutetrabenazine Deutetrabenazine Canagliflozin may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.
Valbenazine Valbenazine Canagliflozin may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.
Deflazacort Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Canagliflozin.
Safinamide Safinamide Safinamide may increase the orthostatic hypotensive activities of Canagliflozin.
Naldemedine Naldemedine Canagliflozin may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.
Neratinib Neratinib The serum concentration of Canagliflozin can be increased when it is combined with Neratinib.
Enasidenib Enasidenib The serum concentration of Canagliflozin can be increased when it is combined with Enasidenib.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Canagliflozin.
Benznidazole Benznidazole Canagliflozin may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.
Copanlisib Injection Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Canagliflozin.
Delafloxacin Delafloxacin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Delafloxacin.
Abemaciclib Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Canagliflozin.
Betrixaban Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Canagliflozin.
Semaglutide Injection Semaglutide Injection Canagliflozin may increase the hypoglycemic activities of Semaglutide.
Ertugliflozin Ertugliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buprenorphine.
Apalutamide Apalutamide The serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.
Fostamatinib Fostamatinib The risk or severity of hypotension can be increased when Fostamatinib is combined with Canagliflozin.
Avatrombopag Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Canagliflozin.
Baricitinib Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Canagliflozin.
Lofexidine Lofexidine Lofexidine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Plazomicin Injection Plazomicin Injection Canagliflozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Canagliflozin.
Binimetinib Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin.
Ivosidenib Ivosidenib The serum concentration of Ivosidenib can be increased when it is combined with Canagliflozin.
Lusutrombopag Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Canagliflozin.
Elagolix Elagolix The serum concentration of Elagolix can be increased when it is combined with Canagliflozin.
Dacomitinib Dacomitinib The serum concentration of Dacomitinib can be increased when it is combined with Canagliflozin.
Duvelisib Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Canagliflozin.
Omadacycline Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Canagliflozin.
Sarecycline Sarecycline The serum concentration of Canagliflozin can be increased when it is combined with Sarecycline.
Stiripentol Stiripentol Canagliflozin may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.
Talazoparib Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Canagliflozin.
Gilteritinib Gilteritinib The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin.
Glasdegib Glasdegib The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin.
Larotrectinib Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Canagliflozin.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.
Rifamycin Rifamycin The serum concentration of Rifamycin can be increased when it is combined with Canagliflozin.
Prucalopride Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.
Magnesium Citrate Magnesium Citrate The risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium citrate.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Erdafitinib Erdafitinib The serum concentration of Canagliflozin can be increased when it is combined with Erdafitinib.
Solriamfetol Solriamfetol Canagliflozin may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.
Darolutamide Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin.
Entrectinib Entrectinib The serum concentration of Entrectinib can be increased when it is combined with Canagliflozin.
Istradefylline Istradefylline The serum concentration of Canagliflozin can be increased when it is combined with Istradefylline.
Pitolisant Pitolisant The serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Canagliflozin.
Lefamulin Lefamulin Canagliflozin may decrease the excretion rate of Lefamulin which could result in a higher serum level.
Phenytoin Injection Phenytoin Injection The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.
Fosphenytoin Injection Fosphenytoin Injection The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.
Lasmiditan Lasmiditan The serum concentration of Canagliflozin can be increased when it is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Canagliflozin.
Tazemetostat Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Canagliflozin.
Cenobamate Cenobamate The serum concentration of Canagliflozin can be decreased when it is combined with Cenobamate.
Teprotumumab-trbw Injection Teprotumumab-trbw Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Teprotumumab.
Selumetinib Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Canagliflozin.
Rimegepant Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Canagliflozin.
Tucatinib Tucatinib Canagliflozin may decrease the excretion rate of Tucatinib which could result in a higher serum level.
Remdesivir Injection Remdesivir Injection The serum concentration of Remdesivir can be increased when it is combined with Canagliflozin.
Ripretinib Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Canagliflozin.
Lemborexant Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Canagliflozin.
Fostemsavir Fostemsavir The serum concentration of Fostemsavir can be increased when it is combined with Canagliflozin.
Octreotide Octreotide The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.
Belantamab Mafodotin-blmf Injection Belantamab Mafodotin-blmf Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Canagliflozin.
Pralsetinib Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Canagliflozin can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The serum concentration of Relugolix can be increased when it is combined with Canagliflozin.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.
Viloxazine Viloxazine Canagliflozin may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Indomethacin Indomethacin The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Canagliflozin.
Mefenamic Acid Mefenamic Acid The metabolism of Canagliflozin can be decreased when combined with Mefenamic acid.
Naproxen Naproxen Naproxen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Isotretinoin Isotretinoin Isotretinoin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Sucralfate Sucralfate Sucralfate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Floxuridine Floxuridine Floxuridine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Phenobarbital Phenobarbital The serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.
Metaxalone Metaxalone Metaxalone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Levorphanol Levorphanol The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levorphanol.
Primidone Primidone The serum concentration of Canagliflozin can be decreased when it is combined with Primidone.
Methsuximide Methsuximide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.
Chlorpromazine Chlorpromazine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorpromazine.
Diazepam Diazepam Diazepam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Oxazepam Oxazepam Oxazepam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Flurazepam Flurazepam Flurazepam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Clorazepate Clorazepate Clorazepic acid may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Lorazepam Lorazepam Lorazepam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Phenoxybenzamine Phenoxybenzamine The risk or severity of adverse effects can be increased when Canagliflozin is combined with Phenoxybenzamine.
Carmustine Carmustine Carmustine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Amantadine Amantadine Amantadine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Codeine Codeine Codeine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Bromocriptine Bromocriptine Canagliflozin may increase the hypoglycemic activities of Bromocriptine.
Tranylcypromine Tranylcypromine Tranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.
Phenelzine Phenelzine Phenelzine may increase the orthostatic hypotensive activities of Canagliflozin.
Procarbazine Procarbazine Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin.
Tetracycline Tetracycline Tetracycline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Thioridazine Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.
Bleomycin Bleomycin Bleomycin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Sulfadiazine Sulfadiazine Canagliflozin may increase the hypoglycemic activities of Sulfadiazine.
Oxycodone Oxycodone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxycodone.
Methadone Methadone Methadone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Benztropine Benztropine Benzatropine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline Maprotiline Maprotiline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Azathioprine Azathioprine Azathioprine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Phentermine Phentermine The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phentermine.
Methylphenidate Methylphenidate Methylphenidate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Amoxapine Amoxapine Amoxapine may decrease the hypoglycemic activities of Canagliflozin.
Sulfasalazine Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Canagliflozin.
Hydrocortisone Hydrocortisone The risk or severity of hyperglycemia can be increased when Canagliflozin is combined with Hydrocortisone.
Doxorubicin Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.
Dactinomycin Dactinomycin The serum concentration of Canagliflozin can be increased when it is combined with Dactinomycin.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Carbamazepine Carbamazepine The metabolism of Canagliflozin can be increased when combined with Carbamazepine.
Methyldopa Methyldopa Methyldopa may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Clonidine Clonidine The risk or severity of adverse effects can be increased when Canagliflozin is combined with Clonidine.
Prazosin Prazosin The risk or severity of adverse effects can be increased when Canagliflozin is combined with Prazosin.
Hydralazine Hydralazine Hydralazine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Cimetidine Cimetidine Cimetidine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Warfarin Warfarin Canagliflozin may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam Clonazepam Clonazepam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Loperamide Loperamide The serum concentration of Canagliflozin can be increased when it is combined with Loperamide.
Promethazine Promethazine Promethazine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Nitrofurantoin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Digoxin Digoxin The serum concentration of Digoxin can be increased when it is combined with Canagliflozin.
Loxapine Loxapine The serum concentration of Canagliflozin can be increased when it is combined with Loxapine.
Chloroquine Chloroquine Chloroquine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Quinine Quinine The serum concentration of Canagliflozin can be increased when it is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Canagliflozin.
Triamterene Triamterene Triamterene may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Lactulose Lactulose The risk or severity of adverse effects can be increased when Canagliflozin is combined with Lactulose.
Chlorothiazide Chlorothiazide The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.
Chlorthalidone Chlorthalidone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.
Metolazone Metolazone The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital Secobarbital The serum concentration of Canagliflozin can be decreased when it is combined with Secobarbital.
Desipramine Desipramine Desipramine may decrease the hypoglycemic activities of Canagliflozin.
Amitriptyline Amitriptyline Amitriptyline may decrease the hypoglycemic activities of Canagliflozin.
Imipramine Imipramine The serum concentration of Canagliflozin can be increased when it is combined with Imipramine.
Probenecid Probenecid The therapeutic efficacy of Canagliflozin can be increased when used in combination with Probenecid.
Quinidine Quinidine The serum concentration of Quinidine can be increased when it is combined with Canagliflozin.
Procainamide Procainamide Canagliflozin may decrease the excretion rate of Procainamide which could result in a higher serum level.
Isoniazid Isoniazid Isoniazid may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pyrazinamide Pyrazinamide Pyrazinamide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Rifampin Rifampin The serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.
Disopyramide Disopyramide Canagliflozin may increase the hypoglycemic activities of Disopyramide.
Tamoxifen Tamoxifen The serum concentration of Canagliflozin can be increased when it is combined with Tamoxifen.
Butabarbital Butabarbital The serum concentration of Canagliflozin can be decreased when it is combined with Butabarbital.
Levothyroxine Levothyroxine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levothyroxine.
Liothyronine Liothyronine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Liothyronine.
Methimazole Methimazole Canagliflozin may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.
Chlorpropamide Chlorpropamide Canagliflozin may increase the hypoglycemic activities of Chlorpropamide.
Tolbutamide Tolbutamide Canagliflozin may increase the hypoglycemic activities of Tolbutamide.
Tolazamide Tolazamide Canagliflozin may increase the hypoglycemic activities of Tolazamide.
Niacin Niacin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.
Baclofen Baclofen The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Baclofen.
Ethambutol Ethambutol Ethambutol may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methyclothiazide Methyclothiazide The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
Hydrochlorothiazide Hydrochlorothiazide The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.
Dantrolene Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Canagliflozin.
Chlorzoxazone Chlorzoxazone Chlorzoxazone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pyridoxine Pyridoxine Pyridoxine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Folic Acid Folic Acid Folic acid may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Danazol Danazol The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Danazol.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propranolol.
Minoxidil Minoxidil The risk or severity of adverse effects can be increased when Canagliflozin is combined with Minoxidil.
Pseudoephedrine Pseudoephedrine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pseudoephedrine.
Nortriptyline Nortriptyline The serum concentration of Canagliflozin can be increased when it is combined with Nortriptyline.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Phytonadione Phytonadione Phylloquinone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Nadolol Nadolol The therapeutic efficacy of Nadolol can be increased when used in combination with Canagliflozin.
Butorphanol Injection Butorphanol Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nalbuphine.
Allopurinol Allopurinol Allopurinol may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Fluoxymesterone Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Canagliflozin.
Clomiphene Clomiphene The serum concentration of Clomifene can be increased when it is combined with Canagliflozin.
Flavoxate Flavoxate Flavoxate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Papaverine Papaverine The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.
Colchicine Colchicine The serum concentration of Colchicine can be increased when it is combined with Canagliflozin.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dacarbazine Dacarbazine Dacarbazine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Acetazolamide Acetazolamide The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetazolamide.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ketoconazole Ketoconazole The serum concentration of Canagliflozin can be increased when it is combined with Ketoconazole.
Pyrantel Pyrantel Canagliflozin may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.
Vincristine Injection Vincristine Injection The excretion of Vincristine can be decreased when combined with Canagliflozin.
Captopril Captopril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Canagliflozin.
Dipyridamole Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.
Isoxsuprine Isoxsuprine The risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.
Vinblastine Vinblastine The serum concentration of Canagliflozin can be increased when it is combined with Vinblastine.
Ethacrynic Acid Ethacrynic Acid The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Metoprolol Metoprolol The therapeutic efficacy of Metoprolol can be increased when used in combination with Canagliflozin.
Aspirin Aspirin The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Canagliflozin.
Salsalate Salsalate Salsalate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Alprazolam Alprazolam Canagliflozin may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.
Temazepam Temazepam Temazepam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam Triazolam Canagliflozin may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine Dicyclomine Dicyclomine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Propantheline Propantheline Propantheline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Trimethoprim Trimethoprim Trimethoprim may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Diltiazem Diltiazem The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Canagliflozin.
Nifedipine Nifedipine Nifedipine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Timolol Timolol The therapeutic efficacy of Timolol can be increased when used in combination with Canagliflozin.
Verapamil Verapamil The serum concentration of Canagliflozin can be increased when it is combined with Verapamil.
Atenolol Atenolol The therapeutic efficacy of Canagliflozin can be increased when used in combination with Atenolol.
Pindolol Pindolol The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pindolol.
Cisplatin Injection Cisplatin Injection Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal The metabolism of Canagliflozin can be decreased when combined with Diflunisal.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Bumetanide Bumetanide The risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.
Etoposide Etoposide The serum concentration of Canagliflozin can be increased when it is combined with Etoposide.
Glyburide Glyburide Canagliflozin may increase the hypoglycemic activities of Glyburide.
Glipizide Glipizide Canagliflozin may increase the hypoglycemic activities of Glipizide.
Indapamide Indapamide The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.
Amoxicillin Amoxicillin Amoxicillin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Oxacillin Injection Oxacillin Injection Oxacillin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pentoxifylline Pentoxifylline Pentoxifylline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pentamidine Injection Pentamidine Injection Canagliflozin may increase the hypoglycemic activities of Pentamidine.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Labetalol Labetalol The therapeutic efficacy of Canagliflozin can be increased when used in combination with Labetalol.
Auranofin Auranofin Auranofin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Leuprolide Injection Leuprolide Injection The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.
Gemfibrozil Gemfibrozil Gemfibrozil may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Guanabenz Guanabenz Canagliflozin may increase the hypotensive activities of Guanabenz.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Enalapril Enalapril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Canagliflozin.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Amiodarone Amiodarone The serum concentration of Amiodarone can be increased when it is combined with Canagliflozin.
Aztreonam Injection Aztreonam Injection Aztreonam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Buspirone Buspirone Buspirone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ciprofloxacin Ciprofloxacin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.
Mesalamine Mesalamine Mesalazine may increase the hypoglycemic activities of Canagliflozin.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fluoxetine Fluoxetine The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin.
Nimodipine Nimodipine The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Canagliflozin.
Clozapine Clozapine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.
Estazolam Estazolam Estazolam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ofloxacin Ofloxacin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ofloxacin.
Didanosine Didanosine Didanosine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Pentostatin Injection Pentostatin Injection Pentostatin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Clarithromycin Clarithromycin The serum concentration of Canagliflozin can be increased when it is combined with Clarithromycin.
Benazepril Benazepril The risk or severity of hypoglycemia can be increased when Benazepril is combined with Canagliflozin.
Etodolac Etodolac Etodolac may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Felodipine Felodipine The risk or severity of hypoglycemia can be increased when Felodipine is combined with Canagliflozin.
Fosinopril Fosinopril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Fosinopril is combined with Canagliflozin.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pravastatin Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Canagliflozin.
Quinapril Quinapril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Quinapril is combined with Canagliflozin.
Ramipril Ramipril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramipril is combined with Canagliflozin.
Simvastatin Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Canagliflozin.
Amlodipine Amlodipine The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Canagliflozin.
Itraconazole Itraconazole The serum concentration of Canagliflozin can be increased when it is combined with Itraconazole.
Lisinopril Lisinopril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Canagliflozin.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Sotalol Sotalol The risk or severity of hypoglycemia can be increased when Sotalol is combined with Canagliflozin.
Bisoprolol Bisoprolol The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bisoprolol.
Doxazosin Doxazosin The risk or severity of adverse effects can be increased when Canagliflozin is combined with Doxazosin.
Terazosin Terazosin The risk or severity of adverse effects can be increased when Canagliflozin is combined with Terazosin.
Isradipine Isradipine Isradipine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Venlafaxine Venlafaxine The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Canagliflozin.
Fluvoxamine Fluvoxamine The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Canagliflozin.
Nefazodone Nefazodone The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Canagliflozin.
Lamotrigine Lamotrigine Lamotrigine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Losartan Losartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tramadol Tramadol Tramadol may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Moexipril Moexipril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Moexipril is combined with Canagliflozin.
Ifosfamide Injection Ifosfamide Injection Ifosfamide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Nicardipine Nicardipine The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Canagliflozin.
Bupropion Bupropion Bupropion may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ticlopidine Ticlopidine Ticlopidine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Saquinavir Saquinavir The serum concentration of Saquinavir can be increased when it is combined with Canagliflozin.
Dalteparin Injection Dalteparin Injection The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Canagliflozin.
Nisoldipine Nisoldipine Nisoldipine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Lamivudine Lamivudine Lamivudine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Amifostine Injection Amifostine Injection The risk or severity of adverse effects can be increased when Amifostine is combined with Canagliflozin.
Acarbose Acarbose Canagliflozin may increase the hypoglycemic activities of Acarbose.
Glimepiride Glimepiride Canagliflozin may increase the hypoglycemic activities of Glimepiride.
Gemcitabine Injection Gemcitabine Injection The serum concentration of Canagliflozin can be increased when it is combined with Gemcitabine.
Indinavir Indinavir The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indinavir.
Ritonavir Ritonavir The metabolism of Canagliflozin can be increased when combined with Ritonavir.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Meropenem Injection Meropenem Injection Meropenem may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Clomipramine Clomipramine Clomipramine may decrease the hypoglycemic activities of Canagliflozin.
Fosfomycin Fosfomycin Fosfomycin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Trandolapril Trandolapril The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Trandolapril is combined with Canagliflozin.
Topiramate Topiramate Topiramate may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Valsartan Valsartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Valsartan.
Insulin Lispro Injection Insulin Lispro Injection Canagliflozin may increase the hypoglycemic activities of Insulin lispro.
Pramipexole Pramipexole Pramipexole may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Nelfinavir Nelfinavir The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nelfinavir.
Fexofenadine Fexofenadine The serum concentration of Canagliflozin can be increased when it is combined with Fexofenadine.
Carvedilol Carvedilol The therapeutic efficacy of Canagliflozin can be increased when used in combination with Carvedilol.
Nilutamide Nilutamide Nilutamide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Flutamide Flutamide Flutamide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Selegiline Selegiline Selegiline may increase the orthostatic hypotensive activities of Canagliflozin.
Sertraline Sertraline The risk or severity of hypoglycemia can be increased when Sertraline is combined with Canagliflozin.
Propafenone Propafenone The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propafenone.
Irbesartan Irbesartan The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Irbesartan.
Tamsulosin Tamsulosin Tamsulosin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Ropinirole Ropinirole The risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.
Quetiapine Quetiapine The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cetirizine Cetirizine Cetirizine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Paroxetine Paroxetine The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.
Tolcapone Tolcapone Tolcapone may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Citalopram Citalopram The risk or severity of hypoglycemia can be increased when Citalopram is combined with Canagliflozin.
Capecitabine Capecitabine Capecitabine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Efavirenz Efavirenz The serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.
Abacavir Abacavir Abacavir may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Sildenafil Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Canagliflozin.
Pioglitazone Pioglitazone Canagliflozin may increase the hypoglycemic activities of Pioglitazone.
Celecoxib Celecoxib The therapeutic efficacy of Canagliflozin can be increased when used in combination with Celecoxib.
Rosiglitazone Rosiglitazone Canagliflozin may increase the hypoglycemic activities of Rosiglitazone.
Tolterodine Tolterodine Tolterodine may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Thalidomide Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.
Oseltamivir Oseltamivir Oseltamivir may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Balsalazide Balsalazide Balsalazide may increase the hypoglycemic activities of Canagliflozin.
Nateglinide Nateglinide Canagliflozin may increase the hypoglycemic activities of Nateglinide.
Rabeprazole Rabeprazole Rabeprazole may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists